1.
Blottner, D. & Salanova, M. The Neuromuscular System: From Earth to Space Life Science : Neuromuscular Cell Signalling in Disuse and Exercise. vol. Springer briefs in space life sciences (Springer, Cham, 2015).
2.
Benson, M. K. D. Children’s Neuromuscular Disorders. (Springer, London, 2011).
3.
Shaibani, A. A Video Atlas of Neuromuscular Disorders. (Oxford University Press, 2014). doi:10.1093/med/9780199898152.001.0001.
4.
Oxford Textbook of Neuromuscular Disorders. vol. Oxford textbooks in clinical neurology (Oxford University Press, [Oxford], 2014).
5.
Kernell, D. The Motoneurone and Its Muscle Fibres. (Oxford University Press, 2006). doi:10.1093/acprof:oso/9780198526551.001.0001.
6.
Amato, A. A. & Russell, J. A. Neuromuscular Disorders. (McGraw-Hill, New York, 2008).
7.
Applied Neurogenomics. vol. Neuromethods (Humana Press, New York, NY, 2015).
8.
Davies, A. M. Regulation of Neuronal Survival by Neurotrophins in the Developing Peripheral Nervous System. in Patterning and Cell Type Specification in the Developing CNS and PNS 303–311 (Elsevier, 2013). doi:10.1016/B978-0-12-397265-1.00095-2.
9.
Gordon, T. & Sulaiman, O. A. Nerve Regeneration in the Peripheral Nervous System. in Neuroglia (ed. Kettenmann, H.) 701–714 (Oxford University Press, 2012). doi:10.1093/med/9780199794591.003.0055.
10.
Welch, M. B. & Brummett, C. M. Peripheral Nervous SystemAnatomy and Function. in Neuroscientific Foundations of Anesthesiology (eds Mashour, G. A. & Lydic, R.) 133–140 (Oxford University Press, 2011). doi:10.1093/med/9780195398243.003.0067.
11.
Rossor, A. M., Tomaselli, P. J. & Reilly, M. M. Recent advances in the genetic neuropathies. Current Opinion in Neurology (2016) doi:10.1097/WCO.0000000000000373.
12.
Rossor, A. M., Evans, M. R. B. & Reilly, M. M. A practical approach to the genetic neuropathies. Practical Neurology 15, 187–198 (2015).
13.
AM Rossor. Recent advances in the genetic neuropathies. Current opinion in neurology 29, (2016).
14.
Reilly, M. & Fridman, V. Inherited Neuropathies. Seminars in Neurology 35, 407–423 (2015).
15.
Rossor, A. M., Evans, M. R. B. & Reilly, M. M. A practical approach to the genetic neuropathies. Practical Neurology 15, 187–198 (2015).
16.
Pasterkamp, R. J. Getting neural circuits into shape with semaphorins. Nature Reviews Neuroscience 13, 605–618 (2012).
17.
R Klein. Role of neurotrophins in mouse neuronal development. The FASEB Journal 8, 738–744 (1994).
18.
Schlosser, G. Induction and specification of cranial placodes. Developmental Biology 294, 303–351 (2006).
19.
Thiede-Stan, N. K. & Schwab, M. E. Attractive and repulsive factors act through multi-subunit receptor complexes to regulate nerve fiber growth. Journal of Cell Science 128, 2403–2414 (2015).
20.
Irina Dudanova. Genetic Evidence for a Contribution of EphA:EphrinA Reverse Signaling to Motor Axon Guidance. Journal of Neuroscience 32, 5209–5215 (2012).
21.
Wang, L., Klein, R., Zheng, B. & Marquardt, T. Anatomical Coupling of Sensory and Motor Nerve Trajectory via Axon Tracking. Neuron 71, 263–277 (2011).
22.
Van Battum, E. Y., Brignani, S. & Pasterkamp, R. J. Axon guidance proteins in neurological disorders. The Lancet Neurology 14, 532–546 (2015).
23.
Kao, T.-J., Law, C. & Kania, A. Eph and ephrin signaling: Lessons learned from spinal motor neurons. Seminars in Cell & Developmental Biology 23, 83–91 (2012).
24.
Byung-Yong Park. Induction and Segregation of the Vertebrate Cranial Placodes. (2010).
25.
Taniguchi, M. et al. Disruption of Semaphorin III/D Gene Causes Severe Abnormality in Peripheral Nerve Projection. Neuron 19, 519–530 (1997).
26.
Ebens, A. et al. Hepatocyte Growth Factor/Scatter Factor Is an Axonal Chemoattractant and a Neurotrophic Factor for Spinal Motor Neurons. Neuron 17, 1157–1172 (1996).
27.
A. Caton. The branchial arches and HGF are growth-promoting and chemoattractant for cranial motor axons. Development 127, 1751–1766.
28.
Conover, J. C. et al. Neuronal deficits, not involving motor neurons, in mice lacking BDNF and/or NT4. Nature 375, 235–238 (1995).
29.
Jessen, K. R. & Mirsky, R. The origin and development of glial cells in peripheral nerves. Nature Reviews Neuroscience 6, 671–682 (2005).
30.
Monk, K. R., Feltri, M. L. & Taveggia, C. New insights on schwann cell development. Glia 63, 1376–1393 (2015).
31.
Jessen, K. R., Mirsky, R. & Lloyd, A. C. Schwann Cells: Development and Role in Nerve Repair. Cold Spring Harbor Perspectives in Biology 7, (2015).
32.
Salzer, J. L. Schwann Cell Myelination. Cold Spring Harbor Perspectives in Biology 7, (2015).
33.
Arthur-Farraj, P. J. et al. c-Jun Reprograms Schwann Cells of Injured Nerves to Generate a Repair Cell Essential for Regeneration. Neuron 75, 633–647 (2012).
34.
Brosius Lutz, A. & Barres, B. A. Contrasting the Glial Response to Axon Injury in the Central and Peripheral Nervous Systems. Developmental Cell 28, 7–17 (2014).
35.
Jessen, K. R. & Mirsky, R. The repair Schwann cell and its function in regenerating nerves. The Journal of Physiology 594, 3521–3531 (2016).
36.
Auer-Grumbach, M. Hereditary sensory and autonomic neuropathies. in Peripheral Nerve Disorders vol. 115 893–906 (Elsevier, 2013).
37.
Davidson, G. L. et al. Frequency of mutations in the genes associated with hereditary sensory and autonomic neuropathy in a UK cohort. Journal of Neurology 259, 1673–1685 (2012).
38.
Rossor, A. M., Evans, M. R. B. & Reilly, M. M. A practical approach to the genetic neuropathies. Practical Neurology 15, 187–198 (2015).
39.
Chhabra, A. Peripheral MR Neurography. Neuroimaging Clinics of North America 24, 79–89 (2014).
40.
Purves, D. Neuroscience. (National Library of Medicine, Bethesda, 2001).
41.
Effects of axon diameter and myelination (video) | Khan Academy. https://www.khanacademy.org/science/health-and-medicine/nervous-system-and-sensory-infor/neuron-membrane-potentials-2014-03-27T17:58:17.207Z/v/effects-of-axon-diameter-and-myelination.
42.
Nerve Signaling. https://www.nobelprize.org/educational/medicine/nerve_signaling/index.html.
43.
Duncan, J. S., Winston, G. P., Koepp, M. J. & Ourselin, S. Brain imaging in the assessment for epilepsy surgery. The Lancet Neurology 15, 420–433 (2016).
44.
Nowell, M. et al. Resection planning in extratemporal epilepsy surgery using 3D multimodality imaging and intraoperative MRI. British Journal of Neurosurgery 31, 468–470 (2017).
45.
Vakharia, V. N. et al. Accuracy of intracranial electrode placement for stereoelectroencephalography: A systematic review and meta-analysis. Epilepsia 58, 921–932 (2017).
46.
Michell, A. Understanding EMG. (Oxford University Press, 2013). doi:10.1093/med/9780199595501.001.0001.
47.
Preston, D. C. & Shapiro, B. E. Electromyography and Neuromuscular Disorders: Clinical-Electrophysiologic Correlations. (Elsevier Saunders, London, 2013).
48.
Top tips for writing a lay summary | The Academy of Medical Sciences. https://acmedsci.ac.uk/more/news/10-tips-for-writing-a-lay-summary.
49.
How to Write a Lay Summary | Digital Curation Centre. http://www.dcc.ac.uk/resources/how-guides/write-lay-summary.
50.
Free guides. http://www.plainenglish.co.uk/free-guides.html.
51.
Part two - The specifics - Access to Understanding. http://www.access2understanding.org/guidance/part-two-the-specifics/.
52.
Readable | Free Readability Test Tool. https://www.webpagefx.com/tools/read-able/.
53.
Rees, J. H. Paraneoplastic syndromes: when to suspect, how to confirm, and how to manage. Journal of Neurology, Neurosurgery & Psychiatry 75, ii43–ii50 (2004).
54.
Antoine, J.-C. & Camdessanché, J.-P. Paraneoplastic disorders of the peripheral nervous system. La Presse Médicale 42, e235–e244 (2013).
55.
How to Write a Lay Summary | DCC How-to Guides. http://www.dcc.ac.uk/resources/how-guides/.
56.
Rossor, A. M., Evans, M. R. B. & Reilly, M. M. A practical approach to the genetic neuropathies. Practical Neurology 15, 187–198 (2015).
57.
Rossor, A. M., Kalmar, B., Greensmith, L. & Reilly, M. M. The distal hereditary motor neuropathies. Journal of Neurology, Neurosurgery & Psychiatry 83, 6–14 (2012).
58.
Rossor, A. M. et al. Peripheral neuropathy in complex inherited diseases: an approach to diagnosis. Journal of Neurology, Neurosurgery & Psychiatry 88, 846–863 (2017).
59.
Carr, A. S. et al. A study of the neuropathy associated with transthyretin amyloidosis (ATTR) in the UK. Journal of Neurology, Neurosurgery & Psychiatry 87, 620–627 (2016).
60.
Hawkins, P. N. et al. Evolving landscape in the management of transthyretin amyloidosis. Annals of Medicine 47, 625–638 (2015).
61.
Plante-Bordeneuve, V. et al. Diagnostic pitfalls in sporadic transthyretin familial amyloid polyneuropathy (TTR-FAP). Neurology 69, 693–698 (2007).
62.
Dubrey, S., Ackermann, E. & Gillmore, J. The transthyretin amyloidoses: advances in therapy. Postgraduate Medical Journal 91, 439–448 (2015).
63.
Dimachkie, M. M. & Barohn, R. J. Guillain-Barré Syndrome and Variants. Neurologic Clinics 31, 491–510 (2013).
64.
Willison, H. J., Jacobs, B. C. & van Doorn, P. A. Guillain-Barré syndrome. The Lancet 388, 717–727 (2016).
65.
Collins, M. P. & Hadden, R. D. The nonsystemic vasculitic neuropathies. Nature Reviews Neurology 13, 302–316 (2017).
66.
Yates, M. et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Annals of the Rheumatic Diseases 75, 1583–1594 (2016).
67.
Collins, M. P. et al. Peripheral Nerve Society Guideline* on the classification, diagnosis, investigation, and immunosuppressive therapy of non-systemic vasculitic neuropathy: executive summary. Journal of the Peripheral Nervous System 15, 176–184 (2010).
68.
Berthelsen, M. P. et al. Anti-gravity training improves walking capacity and postural balance in patients with muscular dystrophy. Neuromuscular Disorders 24, 492–498 (2014).
69.
Cup, E. H. et al. Exercise Therapy and Other Types of Physical Therapy for Patients With Neuromuscular Diseases: A Systematic Review. Archives of Physical Medicine and Rehabilitation 88, 1452–1464 (2007).
70.
Strength training and aerobic exercise training for muscle disease - van der Kooi - 2005 - The Cochrane Library - Wiley Online Library.
71.
Sveen, M.-L. et al. Resistance training in patients with limb-girdle and becker muscular dystrophies. Muscle & Nerve 47, 163–169 (2013).
72.
Jeppesen, T. D. et al. Aerobic training is safe and improves exercise capacity in patients with mitochondrial myopathy. Brain 129, 3402–3412 (2006).
73.
Balance and walking involvement in facioscapulohumeral dystrophy: a pilot study on the effects of custom lower limb orthoses - European Journal of Physical and Rehabilitation Medicine 2013 April;49(2):169-78 - Minerva Medica - Journals. https://www.minervamedica.it/en/journals/europa-medicophysica/article.php?cod=R33Y2013N02A0169.
74.
Michael P. Wiggs. Can endurance exercise preconditioning prevention disuse muscle atrophy? Frontiers in Physiology 6, (2015).
75.
Keith Baar. Using Molecular Biology to Maximize Concurrent Training. Sports Medicine (Auckland, N.z.) 44, (2014).
76.
Craig, D. M. et al. Utilizing small nutrient compounds as enhancers of exercise-induced mitochondrial biogenesis. Frontiers in Physiology 6, (2015).
77.
Hoier, B. & Hellsten, Y. Exercise-Induced Capillary Growth in Human Skeletal Muscle and the Dynamics of VEGF. Microcirculation 21, 301–314 (2014).
78.
Hardie, D. G. AMPK: A Key Sensor of Fuel and Energy Status in Skeletal Muscle. Physiology 21, 48–60 (2006).
79.
Hawley, J. A., Hargreaves, M., Joyner, M. J. & Zierath, J. R. Integrative Biology of Exercise. Cell 159, 738–749 (2014).
80.
Jones, D. A., Haan, A. de & Round, J. M. Skeletal Muscle from Molecules to Movement: A Textbook of Muscle Physiology for Sport, Exercise, Physiotherapy and Medicine. (Churchill Livingstone, Edinburgh, 2004).
81.
A. M. Gordon. Regulation of Contraction in Striated Muscle. Physiological Reviews 80, 853–924 (2000).
82.
R Bottinelli. Force-velocity properties of human skeletal muscle fibres: myosin heavy chain isoform and temperature dependence. The Journal of Physiology 495, (1996).
83.
Harridge, S. D. R. et al. Whole-muscle and single-fibre contractile properties and myosin heavy chain isoforms in humans. Pflügers Archiv - European Journal of Physiology 432, 913–920 (1996).
84.
By:Hunter, S (Hunter, S); White, M (White, M); Thompson, M (Thompson, M). Techniques to evaluate elderly human muscle function: A physiological basis. JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES 53, (1998).
85.
O’Brien, T. D., Reeves, N. D., Baltzopoulos, V., Jones, D. A. & Maganaris, C. N. In vivo measurements of muscle specific tension in adults and children. Experimental Physiology 95, 202–210 (2010).
86.
Clarke, C. et al. Neurology: A Queen Square Textbook. (Wiley-Blackwell, Chichester, 2009).
87.
Neuromuscular Disease Centre. http://neuromuscular.wustl.edu/.
88.
Richard J. Barohn. A PATTERN RECOGNITION APPROACH TO THE PATIENT WITH A SUSPECTED MYOPATHY. Neurologic clinics 32, (2014).
89.
Wattjes, M. P., Kley, R. A. & Fischer, D. Neuromuscular imaging in inherited muscle diseases. European Radiology 20, 2447–2460 (2010).
90.
Morrow, J. M. et al. MRI biomarker assessment of neuromuscular disease progression: a prospective observational cohort study. The Lancet Neurology 15, 65–77 (2016).
91.
Briggs, D. & Morgan, J. E. Recent progress in satellite cell/myoblast engraftment - relevance for therapy. FEBS Journal 280, 4281–4293 (2013).
92.
Peter S. Zammit. Muscle satellite cells adopt divergent fates: a mechanism for self-renewal? The Journal of Cell Biology 166, (2004).
93.
Boldrin, L. & Morgan, J. E. Activating muscle stem cells: therapeutic potential in muscle diseases. Current Opinion in Neurology 20, 577–582 (2007).
94.
Boldrin, L., Zammit, P. S. & Morgan, J. E. Satellite cells from dystrophic muscle retain regenerative capacity. Stem Cell Research 14, 20–29 (2015).
95.
Ross, J. et al. Defects in Glycosylation Impair Satellite Stem Cell Function and Niche Composition in the Muscles of the Dystrophic Large Mouse. STEM CELLS 30, 2330–2341 (2012).
96.
Ravenscroft, G., Davis, M. R., Lamont, P., Forrest, A. & Laing, N. G. New era in genetics of early-onset muscle disease: Breakthroughs and challenges. Seminars in Cell & Developmental Biology 64, 160–170 (2017).
97.
Ravenscroft, G., Laing, N. G. & Bönnemann, C. G. Pathophysiological concepts in the congenital myopathies: blurring the boundaries, sharpening the focus. Brain 138, 246–268 (2015).
98.
North, K. N. et al. Approach to the diagnosis of congenital myopathies. Neuromuscular Disorders 24, 97–116 (2014).
99.
Quijano-Roy, S., Carlier, R. Y. & Fischer, D. Muscle Imaging in Congenital Myopathies. Seminars in Pediatric Neurology 18, 221–229 (2011).
100.
Kimberly Amburgey. A natural history study of X-linked myotubular myopathy. Neurology 89, (2017).
101.
Irene Colombo. Congenital myopathies: Natural history of a large pediatric cohort. Neurology 84, (2015).
102.
Guidance for Paediatric Physiotherapists - Managing Neuromuscular Disorders. http://apcp.csp.org.uk/publications/guidance-paediatric-physiotherapists-managing-neuromuscular-disorders.
103.
APCP. http://apcp.csp.org.uk/.
104.
Neuromuscular | Department of Neurology. https://neuro.wustl.edu/education/fellowships/neuromuscular/.
105.
Muscular Dystrophy UK. http://www.musculardystrophyuk.org/.
106.
Inherited Metabolic Disease in Adults: A Clinical Guide. (Oxford University Press, [New York], 2016).
107.
Inborn Metabolic Diseases: Diagnosis and Treatment. (Springer, Berlin, 2016).
108.
Hoffmann, G. F., Zschocke, J. & Nyhan, W. L. Inherited Metabolic Diseases: A Clinical Approach. (Springer, Heidelberg, 2009).
109.
Machado, P., Brady, S. & Hanna, M. G. Update in inclusion body myositis. Current Opinion in Rheumatology 25, 763–771 (2013).
110.
Machado, P. M., Dimachkie, M. M. & Barohn, R. J. Sporadic inclusion body myositis. Current Opinion in Neurology 27, 591–598 (2014).
111.
Machado, P. M. et al. Ongoing Developments in Sporadic Inclusion Body Myositis. Current Rheumatology Reports 16, (2014).
112.
Mhoriam Ahmed. Targeting Protein Homeostasis in Sporadic Inclusion Body Myositis. Science translational medicine 8, (2016).
113.
Needham, M. & Mastaglia, F. L. Sporadic inclusion body myositis: A review of recent clinical advances and current approaches to diagnosis and treatment. Clinical Neurophysiology 127, 1764–1773 (2016).
114.
Schröder, R. & Schoser, B. Myofibrillar Myopathies: A Clinical and Myopathological Guide. Brain Pathology 19, 483–492 (2009).
115.
Amato, A. A. & Greenberg, S. A. Inflammatory Myopathies. CONTINUUM: Lifelong Learning in Neurology 19, 1615–1633 (2013).
116.
Olivé, M., Kley, R. A. & Goldfarb, L. G. Myofibrillar myopathies. Current Opinion in Neurology 26, 527–535 (2013).
117.
Carstens, P.-O. & Schmidt, J. Diagnosis, pathogenesis and treatment of myositis: recent advances. Clinical & Experimental Immunology 175, 349–358 (2014).
118.
Dalakas, M. C. Inflammatory Muscle Diseases. New England Journal of Medicine 372, 1734–1747 (2015).
119.
Great Britain. Audit Commission for Local Authorities and the National Health Service in England and Wales. What Seems to Be the Matter Communication (National Health Service Report). (Stationery Office).
120.
T. D. Bunker. An information leaflet for surgical patients. Annals of The Royal College of Surgeons of England 65, (1983).
121.
Toolkit for producing patient information.pdf.
122.
Garner, M., Ning, Z. & Francis, J. A framework for the evaluation of patient information leaflets. Health Expectations 15, 283–294 (2012).
123.
C F George. Prescription information leaflets: a pilot study in general practice. British Medical Journal (Clinical research ed.) 287, (1983).
124.
Hollingsworth, K. G., de Sousa, P. L., Straub, V. & Carlier, P. G. Towards harmonization of protocols for MRI outcome measures in skeletal muscle studies: Consensus recommendations from two TREAT-NMD NMR workshops, 2 May 2010, Stockholm, Sweden, 1–2 October 2009, Paris, France. Neuromuscular Disorders 22, S54–S67 (2012).
125.
Wattjes, M. P. & Fischer, D. Neuromuscular Imaging. (Springer, New York, 2013).
126.
Forbes, S. C. et al. Magnetic Resonance Imaging and Spectroscopy Assessment of Lower Extremity Skeletal Muscles in Boys with Duchenne Muscular Dystrophy: A Multicenter Cross Sectional Study. PLoS ONE 9, (2014).
127.
Glover, G. H. & Schneider, E. Three-point dixon technique for true water/fat decomposition withB0 inhomogeneity correction. Magnetic Resonance in Medicine 18, 371–383 (1991).
128.
Willcocks, R. J. et al. Multicenter prospective longitudinal study of magnetic resonance biomarkers in a large duchenne muscular dystrophy cohort. Annals of Neurology 79, 535–547 (2016).
129.
Jean-Yves Hogrel. Longitudinal functional and NMR assessment of upper limbs in Duchenne muscular dystrophy. Neurology 86, (2016).
130.
American Journal of Roentgenology.
131.
Inherited Metabolic Disease in Adults: A Clinical Guide. (Oxford University Press, [New York], 2016).
132.
Nancy D Leslie. Very Long-Chain Acyl-Coenzyme A Dehydrogenase Deficiency. (2014).
133.
Thomas Wieser. Carnitine Palmitoyltransferase II Deficiency. (2017).
134.
Miguel A Martín. Glycogen Storage Disease Type V. (2014).
135.
Nancy Leslie. Pompe Disease. (2017).
136.
Ørngreen, M. C. & Vissing, J. Treatment Opportunities in Patients With Metabolic Myopathies. Current Treatment Options in Neurology 19, (2017).
137.
Olpin, S. E., Murphy, E., Kirk, R. J., Taylor, R. W. & Quinlivan, R. The investigation and management of metabolic myopathies. Journal of Clinical Pathology 68, 410–417 (2015).
138.
Muntoni, F., Torelli, S. & Ferlini, A. Dystrophin and mutations: one gene, several proteins, multiple phenotypes. The Lancet Neurology 2, 731–740 (2003).
139.
Bushby, K. et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. The Lancet Neurology 9, 77–93 (2010).
140.
Bushby, K. et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. The Lancet Neurology 9, 177–189 (2010).
141.
Ricotti, V. et al. Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy. Journal of Neurology, Neurosurgery & Psychiatry 84, 698–705 (2013).
142.
Goemans, N. M. et al. Systemic Administration of PRO051 in Duchenne’s Muscular Dystrophy. New England Journal of Medicine 364, 1513–1522 (2011).
143.
Mendell, J. R. et al. Eteplirsen for the treatment of Duchenne muscular dystrophy. Annals of Neurology 74, 637–647 (2013).
144.
Mendell, J. R. et al. Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. Annals of Neurology 79, 257–271 (2016).
145.
Kinali, M. et al. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. The Lancet Neurology 8, 918–928 (2009).
146.
Cirak, S. et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. The Lancet 378, 595–605 (2011).
147.
Bushby, K. et al. Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle & Nerve 50, 477–487 (2014).
148.
Victorian Department of Health / University of Melbourne. https://www2.health.vic.gov.au/.
149.
Best Practice in Memory Services: Learning from across England.
150.
Matthews, E. et al. The non-dystrophic myotonias: molecular pathogenesis, diagnosis and treatment. Brain 133, 9–22 (2010).
151.
Venance, S. L. et al. The primary periodic paralyses: diagnosis, pathogenesis and treatment. Brain 129, 8–17 (2006).
152.
Cannon, S. C. Channelopathies of Skeletal Muscle Excitability. in Comprehensive Physiology (ed. Terjung, R.) 761–790 (John Wiley & Sons, Inc., Hoboken, NJ, USA, 2011). doi:10.1002/cphy.c140062.
153.
Tan, S. V. et al. Refined exercise testing can aid dna-based diagnosis in muscle channelopathies. Annals of Neurology 69, 328–340 (2011).
154.
Sharp, L. & Trivedi, J. R. Treatment and Management of Neuromuscular Channelopathies. Current Treatment Options in Neurology 16, (2014).
155.
Paganoni, S. & Amato, A. Electrodiagnostic Evaluation of Myopathies. Physical Medicine and Rehabilitation Clinics of North America 24, 193–207 (2013).
156.
Fuglsang-Frederiksen, A. The role of different EMG methods in evaluating myopathy. Clinical Neurophysiology 117, 1173–1189 (2006).
157.
Ferlini, A., Scotton, C. & Novelli, G. Biomarkers in Rare Diseases. Public Health Genomics 16, 313–321 (2013).
158.
Boers, M (Boers, M); Brooks, P (Brooks, P); Strand, CV (Strand, CV); Tugwell, P (Tugwell, P). The OMERACT filter for outcome measures in rheumatology. JOURNAL OF RHEUMATOLOGY JOURNAL OF RHEUMATOLOGY 25, 198–199 (1998).
159.
Conwit, R. A., Bhanushali, M. J., Porter, J. D., Kaufmann, P. & Gutmann, L. Adding more muscle and nerve to clinical trials. Muscle & Nerve 44, 695–702 (2011).
160.
Qualification Process for Drug Development Tools.
161.
Ahmed, M. et al. Targeting protein homeostasis in sporadic inclusion body myositis. Science Translational Medicine 8, 331ra41-331ra41 (2016).
162.
A Cruz-Martínez. Single fiber electromyography (SFEMG) in mitochondrial diseases (MD). Electromyography and clinical neurophysiology (2004).
163.
Hull, J. et al. British Thoracic Society guideline for respiratory management of children with neuromuscular weakness. Thorax 67, i1–i40 (2012).
164.
American Journal of Respiratory and Critical Care Medicine.
165.
Ward, S. Randomised controlled trial of non-invasive ventilation (NIV) for nocturnal hypoventilation in neuromuscular and chest wall disease patients with daytime normocapnia. Thorax 60, 1019–1024 (2005).
166.
Safety and efficacy of diaphragm pacing in patients with respiratory insufficiency due to amyotrophic lateral sclerosis (DiPALS): a multicentre, open-label, randomised controlled trial. The Lancet Neurology 14, 883–892 (2015).
167.
Woollacott, I. O. C. & Rohrer, J. D. The clinical spectrum of sporadic and familial forms of frontotemporal dementia. Journal of Neurochemistry 138, 6–31 (2016).
168.
Gordon, E., Rohrer, J. D. & Fox, N. C. Advances in neuroimaging in frontotemporal dementia. Journal of Neurochemistry 138, 193–210 (2016).
169.
Li, L., Xiong, W.-C. & Mei, L. Neuromuscular Junction Formation, Aging, and Disorders. Annual Review of Physiology 80, (2018).
170.
Singhal, N. & Martin, P. T. Role of extracellular matrix proteins and their receptors in the development of the vertebrate neuromuscular junction. Developmental Neurobiology 71, 982–1005 (2011).
171.
Nishimune, H. et al. Laminins promote postsynaptic maturation by an autocrine mechanism at the neuromuscular junction. The Journal of Cell Biology 182, 1201–1215 (2008).
172.
Nishimune, H. Active zones of mammalian neuromuscular junctions: formation, density, and aging. Annals of the New York Academy of Sciences 1274, 24–32 (2012).
173.
Rudolf, R., Khan, M. M., Labeit, S. & Deschenes, M. R. Degeneration of Neuromuscular Junction in Age and Dystrophy. Frontiers in Aging Neuroscience 6, (2014).
174.
Otto, M. et al. Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS. Amyotrophic Lateral Sclerosis 13, 1–10 (2012).
175.
Simon, N. G. et al. Quantifying disease progression in amyotrophic lateral sclerosis. Annals of Neurology 76, 643–657 (2014).
176.
Lu, C.-H. et al. Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis. Neurology 84, 2247–2257 (2015).
177.
Caballero-Hernandez, D. et al. The ‘Omics’ of Amyotrophic Lateral Sclerosis. Trends in Molecular Medicine 22, 53–67 (2016).
178.
Michael Benatar. ALS Biomarkers for Therapy Development: State of the Field & Future Directions. Muscle & nerve 53, (2016).
179.
Ulf Andreasson. Update on ultrasensitive technologies to facilitate research on blood biomarkers for central nervous system disorders. Alzheimer’s & Dementia : Diagnosis, Assessment & Disease Monitoring 3, (2016).
180.
Kang, J.-H. et al. The Alzheimer’s Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans. Alzheimer’s & Dementia 11, 772–791 (2015).
181.
Al-Chalabi, A., van den Berg, L. H. & Veldink, J. Gene discovery in amyotrophic lateral sclerosis: implications for clinical management. Nature Reviews Neurology 13, 96–104 (2016).
182.
Carrì, M. T., D’Ambrosi, N. & Cozzolino, M. Pathways to mitochondrial dysfunction in ALS pathogenesis. Biochemical and Biophysical Research Communications 483, 1187–1193 (2017).
183.
Lin, G., Mao, D. & Bellen, H. J. Amyotrophic Lateral Sclerosis Pathogenesis Converges on Defects in Protein Homeostasis Associated with TDP-43 Mislocalization and Proteasome-Mediated Degradation Overload. in Fly Models of Human Diseases vol. 121 111–171 (Elsevier, 2017).
184.
Monahan, Z., Shewmaker, F. & Pandey, U. B. Stress granules at the intersection of autophagy and ALS. Brain Research 1649, 189–200 (2016).
185.
Ruegsegger, C. & Saxena, S. Proteostasis impairment in ALS. Brain Research 1648, 571–579 (2016).
186.
Renton, A. E., Chiò, A. & Traynor, B. J. State of play in amyotrophic lateral sclerosis genetics. Nature Neuroscience 17, 17–23 (2014).
187.
Jessell, T. M. Neuronal specification in the spinal cord: inductive signals and transcriptional codes. Nature Reviews Genetics 1, 20–29 (2000).
188.
Harland, R. Neural induction. Current Opinion in Genetics & Development 10, 357–362 (2000).
189.
Dasen, J. S. & Jessell, T. M. Chapter Six Hox Networks and the Origins of Motor Neuron Diversity. in Hox Genes vol. 88 169–200 (Elsevier, 2009).
190.
Bonanomi, D. & Pfaff, S. L. Motor Axon Pathfinding. Cold Spring Harbor Perspectives in Biology 2, a001735–a001735 (2010).
191.
Darabid, H., Perez-Gonzalez, A. P. & Robitaille, R. Neuromuscular synaptogenesis: coordinating partners with multiple functions. Nature Reviews Neuroscience 15, 703–718 (2014).
192.
Kanning, K. C., Kaplan, A. & Henderson, C. E. Motor Neuron Diversity in Development and Disease. Annual Review of Neuroscience 33, 409–440 (2010).
193.
Ladle, D. R., Pecho-Vrieseling, E. & Arber, S. Assembly of Motor Circuits in the Spinal Cord: Driven to Function by Genetic and Experience-Dependent Mechanisms. Neuron 56, 270–283 (2007).
194.
Robert M. Brownstone. Spinal interneurons providing input to the final common path during locomotion. Progress in brain research 187, (2010).
195.
O’Connor, E. et al. Clinical and research strategies for limb-girdle congenital myasthenic syndromes. Annals of the New York Academy of Sciences (2018) doi:10.1111/nyas.13520.
196.
Andrew G. Engel. Congenital myasthenic syndromes: pathogenesis, diagnosis, and treatment. The Lancet. Neurology 14, (2015).
197.
Cruz, P. M. R., Palace, J. & Beeson, D. Congenital myasthenic syndromes and the neuromuscular junction. Current Opinion in Neurology 27, 566–575 (2014).
198.
Rodríguez Cruz, P. M., Palace, J. & Beeson, D. Inherited disorders of the neuromuscular junction: an update. Journal of Neurology 261, 2234–2243 (2014).
199.
Belaya, K. et al. Mutations in cause congenital myasthenic syndrome and bridge myasthenic disorders with dystroglycanopathies. Brain 138, 2493–2504 (2015).
200.
Rodríguez Cruz, P. M. et al. Congenital myopathies with secondary neuromuscular transmission defects; A case report and review of the literature. Neuromuscular Disorders 24, 1103–1110 (2014).
201.
Crisp, S. J., Kullmann, D. M. & Vincent, A. Autoimmune synaptopathies. Nature Reviews Neuroscience 17, 103–117 (2016).
202.
Gilhus, N. E. Myasthenia Gravis. New England Journal of Medicine 375, 2570–2581 (2016).
203.
Matthew N Meriggioli. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet neurology 8, (2009).
204.
Spillane, J., Beeson, D. J. & Kullmann, D. M. Myasthenia and related disorders of the neuromuscular junction. Journal of Neurology, Neurosurgery & Psychiatry 81, 850–857 (2010).
205.
Orrell, Richard WBarclay, Chris. Diagnosis and management of motor neurone disease. Practitioner 260, 17–21.
206.
Morgan, S. & Orrell, R. W. Pathogenesis of amyotrophic lateral sclerosis. British Medical Bulletin 119, 87–98 (2016).
207.
Fuller, G. & Manford, M. Neurology: An Illustrated Colour Text. (Churchill Livingstone, Edinburgh, 2010).
208.
Couratier, P. et al. Epidemiology of amyotrophic lateral sclerosis: A review of literature. Revue Neurologique 172, 37–45 (2016).
209.
Motor neurone disease: assessment and management | Guidance and guidelines | NICE.
210.
Vincent, A. Timeline: Unravelling the pathogenesis of myasthenia gravis. Nature Reviews Immunology 2, 797–804 (2002).
211.
Leslie Jacobson. Plasma from human mothers of fetuses with severe arthrogryposis multiplex congenita causes deformities in mice. Journal of Clinical Investigation 103, (1999).
212.
Hoch, W. et al. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nature Medicine 7, 365–368 (2001).
213.
Koneczny, I., Cossins, J. & Vincent, A. The role of muscle-specific tyrosine kinase (MuSK) and mystery of MuSK myasthenia gravis. Journal of Anatomy 224, 29–35 (2014).
214.
Viegas, S. et al. Passive and active immunization models of MuSK-Ab positive myasthenia: Electrophysiological evidence for pre and postsynaptic defects. Experimental Neurology 234, 506–512 (2012).
215.
Koneczny, I., Cossins, J., Waters, P., Beeson, D. & Vincent, A. MuSK Myasthenia Gravis IgG4 Disrupts the Interaction of LRP4 with MuSK but Both IgG4 and IgG1-3 Can Disperse Preformed Agrin-Independent AChR Clusters. PLoS ONE 8, (2013).
216.
Crisp, S. J., Kullmann, D. M. & Vincent, A. Autoimmune synaptopathies. Nature Reviews Neuroscience 17, 103–117 (2016).
217.
Beryl B. Cummings. Improving genetic diagnosis in Mendelian disease with transcriptome sequencing. Science translational medicine 9, (2017).
218.
Schofield, D. et al. Cost-effectiveness of massively parallel sequencing for diagnosis of paediatric muscle diseases. npj Genomic Medicine 2, (2017).
219.
O’Grady, G. L. et al. Diagnosis and etiology of congenital muscular dystrophy: We are halfway there. Annals of Neurology 80, 101–111 (2016).
220.
Bönnemann, C. G. et al. Diagnostic approach to the congenital muscular dystrophies. Neuromuscular Disorders 24, 289–311 (2014).
221.
North, K. N. et al. Approach to the diagnosis of congenital myopathies. Neuromuscular Disorders 24, 97–116 (2014).
222.
Menezes, M. P. & North, K. N. Inherited neuromuscular disorders: Pathway to diagnosis. Journal of Paediatrics and Child Health 48, 458–465 (2012).
223.
Milestones timeline : Nature Milestones in DNA. https://www.nature.com/milestones/miledna/timeline.html.
224.
Metzker, M. L. Sequencing technologies — the next generation. Nature Reviews Genetics 11, 31–46 (2010).
225.
Yang, Y. et al. Clinical Whole-Exome Sequencing for the Diagnosis of Mendelian Disorders. New England Journal of Medicine 369, 1502–1511 (2013).
226.
Sun, Y. et al. Next-Generation Diagnostics: Gene Panel, Exome, or Whole Genome? Human Mutation 36, 648–655 (2015).
227.
Ghaoui, R. et al. Use of Whole-Exome Sequencing for Diagnosis of Limb-Girdle Muscular Dystrophy. JAMA Neurology 72, (2015).
228.
Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genetics in Medicine 17, 405–423 (2015).
229.
Gabrielle Natalie Samuel. The UK’s 100,000 Genomes Project: manifesting policymakers’ expectations. New Genetics and Society 36, (2017).
230.
Samuel, G. N. & Farsides, B. Public trust and ‘ethics review’ as a commodity: the case of Genomics England Limited and the UK’s 100,000 genomes project. Medicine, Health Care and Philosophy (2017) doi:10.1007/s11019-017-9810-1.
231.
Vaithinathan, A. G. & Asokan, V. Public health and precision medicine share a goal. Journal of Evidence-Based Medicine 10, 76–80 (2017).
232.
Griffin, B. H., Chitty, L. S. & Bitner-Glindzicz, M. The 100 000 Genomes Project: What it means for paediatrics. Archives of disease in childhood - Education & practice edition 102, 105–107 (2017).
233.
Evers, M. M., Toonen, L. J. A. & van Roon-Mom, W. M. C. Antisense oligonucleotides in therapy for neurodegenerative disorders. Advanced Drug Delivery Reviews 87, 90–103 (2015).
234.
Karin E. Lundin. Oligonucleotide Therapies: The Past and the Present. Human Gene Therapy 26, (2015).
235.
Khorkova, O. & Wahlestedt, C. Oligonucleotide therapies for disorders of the nervous system. Nature Biotechnology 35, 249–263 (2017).
236.
Aartsma-Rus, A. Overview on AON Design. in Exon Skipping (ed. Aartsma-Rus, A.) vol. 867 117–129 (Humana Press, Totowa, NJ, 2012).
237.
Rossor, A. M., Reilly, M. M. & Sleigh, J. N. Antisense oligonucleotides and other genetic therapies made simple. Practical Neurology (2018) doi:10.1136/practneurol-2017-001764.
238.
Wood, N. Neurogenetics. (Cambridge University Press, Cambridge, 2012). doi:10.1017/CBO9781139087711.
239.
Neurology. (John Wiley &;#38; Sons, Ltd, Chichester, UK, 2016). doi:10.1002/9781118486160.
240.
OMIM - Online Mendelian Inheritance in Man. https://www.omim.org/.
241.
Teboul, L., Hérault, Y., Smith, C. & Whitelaw, B. Introduction to Mammalian Genome Special Issue: Genome Editing. Mammalian Genome 28, 235–236 (2017).
242.
Fernández, A., Josa, S. & Montoliu, L. A history of genome editing in mammals. Mammalian Genome 28, 237–246 (2017).
243.
Marie-Christine Birling. Modeling human disease in rodents by CRISPR/Cas9 genome editing. Mammalian Genome 28, (2017).
244.
Greenfield, A. Editing mammalian genomes: ethical considerations. Mammalian Genome 28, 388–393 (2017).
245.
Addgene: CRISPR Guide. https://www.addgene.org/crispr/guide/.
246.
MGI-Mouse Genome Informatics -The international database resource for the laboratory mouse. http://www.informatics.jax.org/.
247.
Rossor, A. M., Tomaselli, P. J. & Reilly, M. M. Recent advances in the genetic neuropathies. Current Opinion in Neurology (2016) doi:10.1097/WCO.0000000000000373.
248.
Rossor, A. M., Evans, M. R. B. & Reilly, M. M. A practical approach to the genetic neuropathies. Practical Neurology 15, 187–198 (2015).
